Explore the frontier of life sciences and healthcare innovation. From breakthrough therapeutics and longevity research to the deep tech investments shaping tomorrow's treatments, discover the trends and breakthroughs redefining global health.
Aptadir Therapeutics raised €40M led by 4BIO Capital to develop RNA inhibitors that reverse methylation at a single gene. Its lead candidate targets Fragile X syndrome. No molecule has reached a patient yet.
Genentech paid Earendil Labs $55 million upfront for AI-designed oncology bispecifics still in discovery, with up to $1.5 billion in milestones. The structure prices uncertainty, and shows what pharma now pays for an AI platform rather than a late-stage pipeline.
Molecular glues spent a decade as an accidental art. On September 25, 2026, Nutshell Therapeutics cleared an FDA IND for NTS231, an AI-designed covalent degrader of NRF2 — the second NRF2 glue in the clinic. The hard endpoint is still missing.
Insilico Medicine moved an AI-designed drug from target to preclinical candidate in 18 months. In September it reported biological-age reduction across six independent proteomic clocks, then opened a longevity toolkit and a vaccine program. What is missing is the endpoint investors actually price.
Enveda closed a $311 million Series E at a $2 billion valuation, double a year ago. Two of its AI-discovered medicines, for eczema and obesity, produced positive early data in 2026. The round tests whether nature's chemistry can beat synthetic design at the clinic.
Parabilis listed on Nasdaq in June with the largest US biotech IPO of 2026, then kept building: a first-in-class β-catenin:TCF inhibitor, a $125M Regeneron partnership and $1.1B in cash. The 2027 Phase 3 desmoid readout will test the platform.
Novartis's pelacarsen lowered Lp(a) sharply but missed the Phase 3 Lp(a)HORIZON cardiovascular endpoint — bruising the case for a drug class built on one of cardiology's strongest genetic signals.
Ultragenyx won the first-ever FDA approval for a Sanfilippo syndrome type A therapy, priced at $3.95 million per patient. The win lands eight days after an Angelman Phase 3 failure cut about 44% of its market value, leaving investors to weigh a first-in-disease asset against a tiny patient pool.